- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06195384
Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors
January 6, 2024 updated by: Second Affiliated Hospital of Guangzhou Medical University
Anti-cancer Neoantigen mRNA Vaccine to Treat Advanced Solid Tumors: Phase I Clinical Trial
The WES and RAN-seq will be performed to identify and verify neoantigens and appropriate mRNA sequences will be verified, manufactured and protected for vaccine production by multiple in vitro and in vivo studies.
Clinical studies will be performed to test anti-cancer function of the mRNA vaccine for immunotherapy of human cancer patients.
In this phase I study, the safety, tolerance, and preliminary efficacy of the mRNA vaccine immunotherapy on human cancers will firstly be evaluated.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
- Choose appropriate patients with advanced solid cancers, with written consent for this study;
- Perform biopsy to get fresh sample for DNA/RNA-seqencings and bioinformatics analysis;
- Produce high quality mRNA vaccine and deliver the vaccine into selected patients via local injections, and follow up closely to collect related results as required;
- To enhance the killing capability, cotreatment the patients with PD1/PDL1/CTLA4 antibodies may be applied;
- Evaluate the clinical results as needed.
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zhenfeng Zhang, MD, PhD
- Phone Number: 0086-020-39195965
- Email: zhangzhf@gzhmu.edu.cn
Study Contact Backup
- Name: Bingjia He, MD
- Phone Number: +862039195965
- Email: 464677938@qq.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
1. Patients with advanced cancer; 2. Life expectancy >12 weeks; 3. Adequate heart, lung, liver, kidney, and blood function; 4. Available high quality vaccine for human use; 5. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
-
Exclusion Criteria:
- Had accepted gene therapy before;
- Severe virus infection such as HBV, HCV, HIV, et al;
- Known HIV positivity;
- Active infectious disease related to bacteria, virus,fungi,et al;
- Other severe diseases that the investigators consider not appropriate;
- Pregnant or lactating women;
- Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day);
- Other conditions that the investigators consider not appropriate.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anti-cancer Neoantigen mRNA Vaccine
Anti-cancer neoantigen mRNA vaccine will be produced to treat advanced solid tumors.
|
Deliver neoantigen mRNA vaccine into patients for anti-ancer therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients with Dose Limiting Toxicity
Time Frame: Six months
|
A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the vaccine, which is irreversible, or life threatening or hematologic or non-hematologic Grade 3-5.
|
Six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of Patients with best response as either complete remission or partial remission.
Time Frame: Six months
|
Response rates will be estimated as the percent of patients whose best response is either complete remission or partial remission by combining the data from the patients.
To compare with historical data, a 95% confidence interval will be calculated for the response rate.
|
Six months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Zhenfeng Zhang, MD, PhD, Second Affiliated Hospital of Guangzhou Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
January 1, 2024
Primary Completion (Estimated)
December 30, 2027
Study Completion (Estimated)
December 30, 2037
Study Registration Dates
First Submitted
December 22, 2023
First Submitted That Met QC Criteria
December 22, 2023
First Posted (Actual)
January 8, 2024
Study Record Updates
Last Update Posted (Actual)
January 9, 2024
Last Update Submitted That Met QC Criteria
January 6, 2024
Last Verified
December 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ZZVACCINE-mRNA-020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor, Adult
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Invitae CorporationRecruitingCancer | Solid Tumor | Solid Tumor, AdultUnited States
-
Sairopa B.V.RecruitingMetastatic Solid Tumor | Solid Tumor, Adult | Refractory CancerUnited States, Moldova, Republic of
-
Institut CurieRecruitingChemotherapy Effect | Solid Tumor, Adult | Solid Tumor, ChildhoodFrance
-
New York Stem Cell Foundation Research InstituteStevens Institute of TechnologyRecruiting
-
JemincareNot yet recruiting
Clinical Trials on Neoantigen mRNA Vaccine
-
Shanghai Jiao Tong University School of MedicineRecruitingMedullary Thyroid Cancer | Pancreatic Neuroendocrine Tumor | Adrenal Cortical Carcinoma | Thymic Neuroendocrine CarcinomaChina
-
Stemirna TherapeuticsPeking University Cancer Hospital & InstituteNot yet recruitingAdvanced Malignant Solid Tumors
-
YueJuan ChengNeoCuraRecruiting
-
Shanghai Zhongshan HospitalNot yet recruitingPosto Perative Hepatocellular Carcinoma
-
Stemirna TherapeuticsRecruitingSolid TumorAustralia, Austria
-
jianming xuNeoCuraRecruitingGastric Cancer | Esophageal Cancer | Liver CancerChina
-
The First Affiliated Hospital of Nanchang UniversityShanghai Dengding BioAI Co.RecruitingAdvanced Malignant Solid TumorsChina
-
Tan Tock Seng HospitalKK Women's and Children's Hospital; Duke-NUS Graduate Medical School; A*StarRecruiting
-
First Hospital of Shijiazhuang CityTianjin Hengjia Biotechnology Development co., LTDUnknownNon Small Cell Lung CancerChina
-
CureVacActive, not recruitingGlioblastomaBelgium, Germany, Netherlands